Article Content
MarketFlick Insights
Pfizer Stalls While Merck Gains Ground Acquisitions and Pipeline Questions Define the Gap
At a glance
- Pfizer has underperformed Merck despite pandemic profits from Paxlovid and Comirnaty.
- A $43 billion acquisition of Seagen has faced headwinds after a Phase 3 ADC setback.
- Pfizer acquired Metsera (~$10 billion) to target obesity, with pivotal data expected next year.
- Analysts remain cautious on Pfizer JPMorgan cut its price target and kept a Neutral rating.
- Mercks recent deals are viewed as better positioned to address the Keytruda patent cliff, supporting investor confidence.
Market Analysis
The leading U.S. pharma stocks are painting a mixed picture. While Eli Lilly has pushed to fresh highs and AbbVie sits not far behind, a clearer split has opened between Merck & Co and Pfizer. Mercks shares have outperformed Pfizers decisively in recent months, a trend that reflects diverging investor sentiment about each companys strategy and near-term prospects.
Pfizers struggles come after an extraordinary pandemic windfall. The company made substantial profits from the antiviral Paxlovid and, together with BioNTech, the COVID-19 vaccine Comirnaty. Flush with cash, Pfizer turned to acquisition-driven growth most notably its 2023 purchase of Seagen for roughly $43 billion, a bet on antibodydrug conjugates (ADCs). Yet some of those bets have not delivered to date. A recent clinical setback with Seagens ADC Sigvotatug Vedotin in a Phase 3 second-line trial for advanced non-small cell lung cancer disappointed investors and analysts alike.
JPMorgan analyst Chris Schott responded to the weak data by trimming his price target on Pfizer from $30 to $28 while keeping a Neutral rating, citing additional readouts expected in 2027. That cautious tone underscores how much Pfizers valuation now hinges on future clinical successes and the payoff from its big-ticket deals.
Strategy and Outlook
Pfizer is also positioning itself in obesity treatments. The company paid about $10 billion for Metsera to build a presence in that fast-growing market and plans to deliver pivotal obesity data next year. Whether Metsera and other acquisitions will produce new revenue engines remains uncertain, though management has clearly prioritized M&A to diversify revenue beyond pandemic-era products.
By contrast, investor optimism around Merck stems from the perception that its recent M&A choices have been more accretive and better timed to blunt the impact of an upcoming patent cliff for its cancer blockbuster Keytruda. Merck has actively been buying growth to prepare for that transition, and the market has rewarded the company with stronger performance relative to Pfizer.
Pfizers path forward will depend on a mix of clinical readouts, successful integration of acquisitions such as Seagen and Metsera, and the demonstration that its pipeline can replace legacy revenue. For now, the gap between Merck and Pfizer reflects a market that favors perceived strategic clarity and near-term growth visibility over past pandemic profits.
In short: Pfizer is in no-mans-land still a major pharmaceutical force, but under pressure to prove that its deal-making and pipeline investments will translate into sustainable growth, while Merck enjoys the benefit of investor confidence in its recent moves.
